Breaking barriers: advancing cellular therapies in autoimmune disease management
Autoimmune diseases occur due to a dysregulation within the immune system, leading to an aberrant assault on the organism’s own tissues. The pathogenesis of these conditions is multifactorial, encompassing intricate interplays among genetic predispositions, environmental determinants, and hormonal f...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1503099/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850065914716749824 |
|---|---|
| author | Yanhong Fu Yanhong Fu Chunjing Feng Chunjing Feng Shan Qin Shan Qin Zhiyao Xing Zhiyao Xing Chong Liu Chong Liu Zichuan Liu Zichuan Liu Hongjian Yu |
| author_facet | Yanhong Fu Yanhong Fu Chunjing Feng Chunjing Feng Shan Qin Shan Qin Zhiyao Xing Zhiyao Xing Chong Liu Chong Liu Zichuan Liu Zichuan Liu Hongjian Yu |
| author_sort | Yanhong Fu |
| collection | DOAJ |
| description | Autoimmune diseases occur due to a dysregulation within the immune system, leading to an aberrant assault on the organism’s own tissues. The pathogenesis of these conditions is multifactorial, encompassing intricate interplays among genetic predispositions, environmental determinants, and hormonal fluctuations. The spectrum of autoimmune diseases is broad, impacting a multitude of organ systems, with notable examples such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), psoriasis, and vitiligo. Despite substantial progress in therapeutic interventions over recent years, a definitive cure for autoimmune diseases has yet to be realized, with existing modalities largely providing palliative care. Cellular therapy is considered the fourth pillar in the management of oncological disorders subsequent to surgical resection, radiotherapy, and chemotherapy. Cellular therapies have shown potential in augmenting immune competence and eliminating of targeted neoplastic cells in a spectrum of cancers. As targeting specific molecules on the surface of autoreactive B and T cells, such as CD19, BCMA, CD20, and CTLA-4, cellular therapies are emerging as promising approaches for the treatment of autoimmune diseases. This review delineates the advancements in the application of cellular therapies applied recently for autoimmune diseases and proposes considerations for the advancement of novel therapeutic strategies. |
| format | Article |
| id | doaj-art-de77bf21831c4fba8ba8574d2a98767c |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-de77bf21831c4fba8ba8574d2a98767c2025-08-20T02:48:53ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-11-011510.3389/fimmu.2024.15030991503099Breaking barriers: advancing cellular therapies in autoimmune disease managementYanhong Fu0Yanhong Fu1Chunjing Feng2Chunjing Feng3Shan Qin4Shan Qin5Zhiyao Xing6Zhiyao Xing7Chong Liu8Chong Liu9Zichuan Liu10Zichuan Liu11Hongjian Yu12School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, ChinaTianjin University and Health-Biotech United Group Joint Laboratory of Innovative Drug Development and Translational Medicine, School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, ChinaTianjin University and Health-Biotech United Group Joint Laboratory of Innovative Drug Development and Translational Medicine, School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, ChinaJiangxi Engineering Research Center for Stem Cell, Jiangxi Health-Biotech Stem Cell Technology Co., Ltd., Shangrao, Jiangxi, ChinaSchool of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, ChinaTianjin University and Health-Biotech United Group Joint Laboratory of Innovative Drug Development and Translational Medicine, School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, ChinaTianjin University and Health-Biotech United Group Joint Laboratory of Innovative Drug Development and Translational Medicine, School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, ChinaJinnan Hospital, Faculty of Medicine, Tianjin Jinnan Hospital, Tianjin University, Tianjin, ChinaSchool of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, ChinaTianjin University and Health-Biotech United Group Joint Laboratory of Innovative Drug Development and Translational Medicine, School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, ChinaSchool of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, ChinaFrontiers Science Center for Synthetic Biology (Ministry of Education), Tianjin University, Tianjin, ChinaJinnan Hospital, Faculty of Medicine, Tianjin Jinnan Hospital, Tianjin University, Tianjin, ChinaAutoimmune diseases occur due to a dysregulation within the immune system, leading to an aberrant assault on the organism’s own tissues. The pathogenesis of these conditions is multifactorial, encompassing intricate interplays among genetic predispositions, environmental determinants, and hormonal fluctuations. The spectrum of autoimmune diseases is broad, impacting a multitude of organ systems, with notable examples such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), psoriasis, and vitiligo. Despite substantial progress in therapeutic interventions over recent years, a definitive cure for autoimmune diseases has yet to be realized, with existing modalities largely providing palliative care. Cellular therapy is considered the fourth pillar in the management of oncological disorders subsequent to surgical resection, radiotherapy, and chemotherapy. Cellular therapies have shown potential in augmenting immune competence and eliminating of targeted neoplastic cells in a spectrum of cancers. As targeting specific molecules on the surface of autoreactive B and T cells, such as CD19, BCMA, CD20, and CTLA-4, cellular therapies are emerging as promising approaches for the treatment of autoimmune diseases. This review delineates the advancements in the application of cellular therapies applied recently for autoimmune diseases and proposes considerations for the advancement of novel therapeutic strategies.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1503099/fullautoimmune diseasescellular therapyB cellsCD19Tregs |
| spellingShingle | Yanhong Fu Yanhong Fu Chunjing Feng Chunjing Feng Shan Qin Shan Qin Zhiyao Xing Zhiyao Xing Chong Liu Chong Liu Zichuan Liu Zichuan Liu Hongjian Yu Breaking barriers: advancing cellular therapies in autoimmune disease management Frontiers in Immunology autoimmune diseases cellular therapy B cells CD19 Tregs |
| title | Breaking barriers: advancing cellular therapies in autoimmune disease management |
| title_full | Breaking barriers: advancing cellular therapies in autoimmune disease management |
| title_fullStr | Breaking barriers: advancing cellular therapies in autoimmune disease management |
| title_full_unstemmed | Breaking barriers: advancing cellular therapies in autoimmune disease management |
| title_short | Breaking barriers: advancing cellular therapies in autoimmune disease management |
| title_sort | breaking barriers advancing cellular therapies in autoimmune disease management |
| topic | autoimmune diseases cellular therapy B cells CD19 Tregs |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1503099/full |
| work_keys_str_mv | AT yanhongfu breakingbarriersadvancingcellulartherapiesinautoimmunediseasemanagement AT yanhongfu breakingbarriersadvancingcellulartherapiesinautoimmunediseasemanagement AT chunjingfeng breakingbarriersadvancingcellulartherapiesinautoimmunediseasemanagement AT chunjingfeng breakingbarriersadvancingcellulartherapiesinautoimmunediseasemanagement AT shanqin breakingbarriersadvancingcellulartherapiesinautoimmunediseasemanagement AT shanqin breakingbarriersadvancingcellulartherapiesinautoimmunediseasemanagement AT zhiyaoxing breakingbarriersadvancingcellulartherapiesinautoimmunediseasemanagement AT zhiyaoxing breakingbarriersadvancingcellulartherapiesinautoimmunediseasemanagement AT chongliu breakingbarriersadvancingcellulartherapiesinautoimmunediseasemanagement AT chongliu breakingbarriersadvancingcellulartherapiesinautoimmunediseasemanagement AT zichuanliu breakingbarriersadvancingcellulartherapiesinautoimmunediseasemanagement AT zichuanliu breakingbarriersadvancingcellulartherapiesinautoimmunediseasemanagement AT hongjianyu breakingbarriersadvancingcellulartherapiesinautoimmunediseasemanagement |